Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ERLEADA vs ANDROID 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erleada (apalutamide) is an androgen receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR, preventing AR nuclear translocation, DNA binding, and transcription of AR target genes. It also inhibits AR-mediated tumor growth and reduces prostate-specific antigen (PSA) levels.
Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.
Treatment of non-metastatic castration-resistant prostate cancer (nm CRPC),Treatment of metastatic castration-sensitive prostate cancer (m CSPC)
Hypogonadism in males (primary and secondary),Delayed puberty in males,Metastatic breast cancer in women (as palliative therapy)
240 mg orally once daily on an empty stomach, taken at least 1 hour before or 2 hours after a meal. Swallow tablets whole.
Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.
Terminal elimination half-life is approximately 20 hours (range 16-24 hours) at steady state, supporting once-daily dosing.
Terminal elimination half-life: 10–100 minutes (testosterone); clinical context: rapid clearance necessitates frequent dosing or use of esters for sustained effect
Primarily metabolized by CYP2C8 and CYP3A4 to form active metabolites (N-desmethyl apalutamide). It is also a strong inducer of CYP3A4 and CYP2C9, and has moderate effects on CYP2C19 and UGTs.
Primarily hepatic via reduction and oxidation; metabolites include androsterone and etiocholanolone; excreted in urine.
Fecal (87.4%) as unchanged drug and metabolites; renal (2.4%) as unchanged drug.
Renal: 90% (as glucuronide and sulfate conjugates, 5–10% unchanged); fecal/biliary: 10%
Highly protein bound (97%) primarily to albumin and α1-acid glycoprotein (AAG).
97–99% (sex hormone-binding globulin and albumin)
Apparent volume of distribution (Vd/F) is approximately 157 L (about 2.2 L/kg for a 70 kg adult), indicating extensive extravascular distribution.
0.3–0.6 L/kg; indicates distribution into lean muscle and sex organs
Oral bioavailability is not determined due to lack of intravenous formulation; after oral administration, absorption is rapid with Tmax of 2 hours under fasting conditions; food increases Cmax by 2- to 4-fold and AUC by 2-fold.
Oral: <5% (methyltestosterone: ~20–25% due to 17α-alkylation); IM: 100%
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease; use with caution.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose or increasing interval; monitor for fluid retention and hypertension.
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate (Child-Pugh B): reduce dose to 120 mg once daily. Severe (Child-Pugh C): not recommended.
Contraindicated in Child-Pugh class B or C cirrhosis. For mild hepatic impairment (Child-Pugh A), start with lower dose (e.g., 12.5 mg every 2 weeks) and titrate based on response and liver function.
Safety and efficacy not established in pediatric patients; no specific pediatric dosing available.
Not recommended for use in pediatric patients (safety and efficacy not established). For male adolescents with hypogonadism, individualize: start at 12.5 mg every 2 weeks and adjust based on testosterone levels and growth.
No specific dose adjustment required based on age alone; monitor for adverse effects (e.g., falls, hypertension) more frequently in elderly patients.
Start with lower initial dose (e.g., 12.5 mg every 2 weeks); monitor prostate-specific antigen (PSA) and hematocrit frequently. Avoid in patients with prostate cancer or untreated sleep apnea.
No boxed warning.
WARNING: Androgens are contraindicated in pregnancy due to masculinization of female fetus. Hepatotoxicity, including peliosis hepatis and hepatic neoplasms, has been reported with prolonged use.
Seizure: Increased risk, especially in patients with predisposing factors; discontinue if seizure occurs.,Falls and fractures: Increased incidence in clinical trials; assess fall and fracture risk.,Cardiovascular effects: Hypertension, especially in patients with pre-existing cardiovascular disease.,Thyroid dysfunction: Monitor thyroid function tests periodically.,Hypercholesterolemia: Monitor lipid profile and manage accordingly.,Hypersensitivity reactions: Including angioedema; discontinue if severe.
Use with caution in patients with hepatic, renal, or cardiovascular disease; may cause gynecomastia, edema, hypercalcemia, and polycythemia; monitor liver function, lipid profile, and hematocrit periodically; may accelerate bone maturation in children; risk of prostate hypertrophy and urethral obstruction.
Pregnancy: Apalutamide can cause fetal harm and is contraindicated in pregnant women.,Severe hypersensitivity to apalutamide or any component of the formulation.
Known or suspected prostate cancer; male breast cancer; pregnancy; lactation; hypersensitivity to methyltestosterone; severe hepatic impairment.
Grapefruit and grapefruit juice may increase apalutamide concentrations; avoid consumption. No other food interactions known.
Take with food containing fat (e.g., avocado, nuts, olive oil) to enhance absorption. Avoid grapefruit juice as it may increase testosterone levels via CYP3A4 inhibition. Limit alcohol due to potential liver effects.
Risk Category X. ERLEADA (apalutamide) can cause fetal harm when administered to a pregnant woman. Nonclinical studies have demonstrated teratogenicity, including skeletal abnormalities and reduced fetal weight, at exposures below the recommended human dose. As male patients exposed to ERLEADA may father a child, a pregnancy test should be conducted for female partners of reproductive potential prior to initiating therapy. Advise male patients to use effective contraception during treatment and for 3 months after the last dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to the fetus.
Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure occurs before 12 weeks gestation. Second and third trimesters: Continued risk of female pseudohermaphroditism, and potential for masculinization of female external genitalia. Androgens can cross the placenta and may also cause skeletal abnormalities and growth retardation. Pregnancy category X.
No data available on the presence of apalutamide in human milk, its effects on the breastfed infant, or its effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from ERLEADA, advise women not to breastfeed during treatment and for at least 3 months after the last dose. The milk-to-plasma ratio is unknown.
Methyltestosterone is excreted into breast milk; M/P ratio not established. May cause virilization in female infants and premature sexual development in male infants. Androgens can suppress lactation. Use during breastfeeding is contraindicated.
ERLEADA is contraindicated in pregnancy. No dose adjustment is recommended for non-pregnant patients; however, due to the risk of fetal harm, use is not recommended during pregnancy. Pharmacokinetic changes of apalutamide specifically during pregnancy have not been studied, and no dose adjustments are recommended as the drug is not used in pregnant women.
Android 25 is contraindicated in pregnancy, so no dosing adjustments are applicable. If used inadvertently, discontinue immediately. No pharmacokinetic data to guide dose changes; avoid use entirely.
ERLEADA (apalutamide) requires concomitant use with a Gn RH analog or bilateral orchiectomy. Monitor for hypertension, hypothyroidism, and hypercholesterolemia. Falls and fractures are increased; assess fracture risk. Use with caution in patients at risk for seizures, as clinical seizures occurred in 0.2% of patients. Dose adjustment for CYP3A4 substrates with narrow therapeutic index.
Android 25 (testosterone undecanoate) requires absorption via lymphatic system; administer with fat-containing meal. Monitor serum testosterone levels 3-5 hours post-dose. Avoid in patients with breast cancer or known or suspected prostate cancer. Risk of polycythemia; check hematocrit before and during therapy.
Take ERLEADA once daily at the same time each day, with or without food. Swallow tablets whole; do not crush or chew.,Use effective contraception during treatment and for 3 months after last dose. ERLEADA can cause fetal harm.,Report any signs of infection, falls, fractures, or seizures immediately. Risk of falls and fractures is increased.,Blood pressure, thyroid function, and cholesterol levels will be monitored regularly. Report symptoms of hypothyroidism like fatigue or cold intolerance.,Avoid grapefruit, grapefruit juice, or products containing grapefruit while on ERLEADA.
Take capsules with meals, especially those containing fat, to improve absorption.,Do not chew or crush capsules; swallow whole.,Report signs of deep vein thrombosis (leg swelling, pain) or pulmonary embolism (sudden dyspnea, chest pain).,Women of reproductive potential should avoid pregnancy; use effective contraception.,Keep out of reach of children; testosterone can cause serious harm if accidentally ingested.,Regular blood tests (testosterone, hematocrit, PSA, lipid profile) are required.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ERLEADA vs ANDROID 25, answered by our medical review team.
ERLEADA is a Androgen Receptor Inhibitor Antineoplastic that works by Erleada (apalutamide) is an androgen receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR, preventing AR nuclear translocation, DNA binding, and transcription of AR target genes. It also inhibits AR-mediated tumor growth and reduces prostate-specific antigen (PSA) levels.. ANDROID 25 is a Androgen that works by Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ERLEADA and ANDROID 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ERLEADA is: 240 mg orally once daily on an empty stomach, taken at least 1 hour before or 2 hours after a meal. Swallow tablets whole.. The standard adult dose of ANDROID 25 is: Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ERLEADA and ANDROID 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ERLEADA is classified as Category C. Risk Category X. ERLEADA (apalutamide) can cause fetal harm when administered to a pregnant woman. Nonclinical studies have demonstrated teratogenicity, including skeletal abnormal. ANDROID 25 is classified as Category C. Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure oc. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.